Combination therapy with IV fosfomycin for adult patients with serious Gram-negative infections: a review of the literature
- 31 August 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 79 (10) , 2421-2459
Abstract
Treatment of patients with serious infections due to resistant Gram-negative bacteria remains highly problematic and has prompted clinicians to use existing antimicrobial agents in innovative ways. One approach gaining increased therapeutic use is combination therapy with IV fosfomycin. This article reviews the preclinical pharmacokinetic/pharmacodynamic (PK/PD) infection model and clinical data surrounding the use of combination therapy with IV fosfomycin for the treatment of serious infections caused by resistant Gram-negative bacteria. Data from dynamic in vitro and animal infection model studies of highly resistant Enterobacterales and non–lactose fermenters are positive and suggest IV fosfomycin in combination with a β-lactam, polymyxin or aminoglycoside produces a synergistic effect that rivals or surpasses that of other aminoglycoside- or polymyxin-containing regimens. Clinical studies performed to date primarily have involved patients with pneumonia and/or bacteraemia due to Klebsiella pneumoniae, Pseudomonas aeruginosa or Acinetobacter baumannii. Overall, the observed success rates with fosfomycin combination regimens were consistent with those reported for other combination regimens commonly used to treat these patients. In studies in which direct treatment comparisons can be derived, the results suggest that patients who received fosfomycin combination therapy had similar or improved outcomes compared with other therapies and combinations, especially when it was used in combination with a β-lactam that (1) targets PBP-3 and (2) has exceptional stability in the presence of β-lactamases. Collectively, the data indicate that combination therapy with IV fosfomycin should be considered as a potential alternative to aminoglycoside or polymyxin combinations for patients with antibiotic-resistant Gram-negative infections when benefits outweigh risks.Keywords
Funding Information
- Zavante Therapeutics, Inc., Delaware, USA
This publication has 116 references indexed in Scilit:
- Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract InfectionsJAMA Network Open, 2022
- Model‐Informed Drug Development for Anti‐Infectives: State of the Art and FutureClinical Pharmacology & Therapeutics, 2021
- Evaluation Strategies for Triple‐Drug Combinations against Carbapenemase‐Producing Klebsiella Pneumoniae in an In Vitro Hollow‐Fiber Infection ModelClinical Pharmacology & Therapeutics, 2021
- Current clinical use of intravenous fosfomycin in ICU patients in two European countriesInfection, 2019
- International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti‐infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical TrialInfectious Diseases and Therapy, 2018
- Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal ImplicationsPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteriaEuropean Journal of Clinical Pharmacology, 2010
- Bactericidal effect of pefloxacin and fosfomycin againstPseudomonas aeruginosa in a rabbit endocarditis model with pharmacokinetics of pefloxacin in humans simulated in vivoEuropean Journal of Clinical Microbiology & Infectious Diseases, 1997
- Fosfomycin-ampicillin versus gentamicin-ampicillin in the treatment of critically Ill patients with pneumoniaInfection, 1986